PATENTED INGREDIENT
LivPhcD® CS-4 Cordyceps Mycelium (Samsoniella hepiali)
LivPhcD® is a CS-4 mycelium ingredient developed by TCM Biotech, identified on its official website as Samsoniella hepiali. Its documentation covers fermentation technology and a human study design; study design alone does not establish clinical efficacy.
INGREDIENT PROFILE
What this ingredient is documented for
- Origin
- Taiwan
- Developer
- TCM Biotech International Corp.
- CS-4 cordyceps mycelium: LivPhcD® is cultured from the CS-4 strain purified by TCM Biotech, scientifically identified as Samsoniella hepiali.
- Adenosine-containing mycelium ingredient: the official website describes LivPhcD® as rich in adenosine, a nucleoside involved in physiological processes including energy metabolism and neurotransmission.
- Patented fermentation process: the official website describes patented fermentation and production techniques, with analysis of fermentation-broth components at different stages to determine suitable cultivation conditions.
- Human study design: the official website outlines a randomized, double-blind, placebo-controlled, parallel-group study with 110 participants over 36 weeks, using daily study doses of 750, 1,500 or 2,250 mg. These are study-design details, not confirmed efficacy findings or personal dosage recommendations.
- Official patent information: the website lists TWI501771, TWI554277, US8858954, US8658181, JP6355689, JP6050099 and EP2644201. Current patent status and scope are subject to the relevant authorities’ records. Source: https://www.livphcd.com.tw/index.php . Manufacturing origin, ingredient specifications and applicable certification documents require supplier confirmation.
Ingredient identity and evidence boundaries
LivPhcD® is cultured CS-4 mycelium identified by the manufacturer as Samsoniella hepiali. It should not be presented as wild Ophiocordyceps sinensis or assumed interchangeable with other cordyceps species and extracts.
The official website describes a randomized, double-blind, placebo-controlled, parallel-group study involving 110 participants over 36 weeks, with daily study doses of 750, 1,500 and 2,250 mg. These are study-design details, not confirmed efficacy findings or personal dosage recommendations.
For procurement, verify strain identity, marker specifications, COA, production origin, microbiological and contaminant testing, and applicable authorization documents. The official patent list provides a starting point for document review; it does not establish current validity, claim scope, or ACC ownership. Finished-product claims require separate assessment for the destination market.
Official ingredient documentation
Manufacturer website checked on 29 October 2026. Product identity, study design and patent references are attributed to the manufacturer.
- LivPhcD® official ingredient, fermentation and study overview
TCM Biotech International Corp.
Primary manufacturer source. Verify current specifications, manufacturing origin, patent scope and licensing directly with the supplier.
View source
FORMULATION
Discuss this ingredient with ACC
Bring this ingredient into a formula, documentation and sourcing conversation with the ACC team.